Inflammation
Showing NaN - NaN of 5
Cardiovascular Risk, Chronic Kidney Disease, Inflammation Trial in Worldwide (Ziltivekimab, Placebo (ziltivekimab))
Recruiting
- Cardiovascular Risk
- +2 more
- Ziltivekimab
- Placebo (ziltivekimab)
-
Birmingham, Alabama
- +768 more
Dec 23, 2022
Chronic Kidney Diseases, Inflammation Trial in United States (Ziltivekimab)
Completed
- Chronic Kidney Diseases
- Inflammation
- Ziltivekimab
-
Birmingham, Alabama
- +48 more
Jul 6, 2021
Inflammation, Rheumatoid Arthritis Trial in Worldwide (NNC0109-0012, )
Terminated
- Inflammation
- Rheumatoid Arthritis
- NNC0109-0012
- placebo
-
Huntington Beach, California
- +139 more
Sep 3, 2018
Inflammation, Rheumatoid Arthritis Trial in Worldwide (NNC0109-0012, )
Terminated
- Inflammation
- Rheumatoid Arthritis
- NNC0109-0012
- placebo
-
Huntsville, Alabama
- +163 more
Sep 3, 2018
Inflammation Trial in Charlotte (Difluprednate, Placebo)
Completed
- Inflammation
- Difluprednate
- Placebo
-
Charlotte, North CarolinaCharlotte Eye, Ear, Nose & Throat
Jun 29, 2011